Cipla Ltd.

Cipla is currently trading at Rs. 380.00, up by 0.85 points or 0.22% from its previous closing of Rs. 379.15 on the BSE.

The scrip opened at Rs. 380.00 and has touched a high and low of Rs. 381.00 and Rs. 374.70 respectively. So far 3, 08,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 435.00 on 09-Jan-2013 and a 52 week low of Rs. 305.50 on 25-Jun-2012.

Last one week high and low of the scrip stood at Rs. 382.25 and Rs. 372.75 respectively. The current market cap of the company is Rs. 30,511 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.08% and 28.32% respectively. 

Cipla has received approval from the South African and Botswana competition authorities for acquisition of Medpro. However, the implementation of the Scheme is still subject to various other approvals and conditions, including regulatory and government approvals. Earlier on May 15, 2013, the company had received a nod from Shareholders of Cipla Medpro South Africa to acquire 100% stake in the foreign company.

Cipla supplies the bulk of the South African company's drugs through a long-standing agreement; however it has never owned a stake in the Cape Town-based company. This development will give Cipla a direct connect to consumers in South Africa. It also helps the company to integrate its marketing or front-end arm in South Africa with its manufacturing, regulatory and research units.